News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Mesothelin Finding Could Lead to Early Detection of Mesothelioma
- New York Attorney Calls for International Ban on Mesothelioma-Causing Asbestos
- Protein Can be Reliable for Diagnosing Malignant Mesothelioma
- Biomarker Successes Remain Elusive For Mesothelioma and Cancer Researchers
- Avastin May Not be Effective for Breast Cancer, But is Still an Option for Mesothelioma
- Options for Funding Mesothelioma Research
- Golf Outing to Raise Funds for Mesothelioma Research
- 3 Year Mesothelioma Survivor Stays Busy Raising Awareness of the Disease
- MesotheliomaHelp Website Offers Mesothelioma-Related FAQs
- CDMRP System Offers Funding Opportunity to Help Military Mesothelioma Sufferers
Tuesday, October 13, 2009
Study: Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Start Date: January 2009
End Date: January 2020
Recruiting Contacts
Andrea Foster, 416-946-4501 ext 5010, Andrea.Foster@Uhn.on.ca
Jennifer Hornby, BSc CCRP 416-340-4857, Jennifer.Hornby@uhn.on.ca
Information
The University Health Network of Toronto is currently recruiting participants for a clinical trial using a combination of Pemetrexed (Alimta) with Cisplatin prior to surgery followed by radiation therapy after surgery. The goal enrollment for the trial is 45 patients that have been diagnosed with malignant pleural mesothelioma but have not yet undergone treatment.
Previous studies have shown that complete removal of mesothelioma is possible in approximately 30% of the patients, with treatment typically continuing with chemotherapy followed by radiation. The chances of the tumor returning after this trimodal therapy remains high, and the chances of long term survival remains low.
According to the trial information, the combination of Pemetrexed (Alimta) with Cisplatin as chemotherapy treatment is likely to benefit, and potentially cure, a group of patients.
For complete information see ClinicalTrials.
Labels: ClinicalTrial, mesothelioma
posted by Nancy Meredith at 1:07 PM
